RESUMO
1alpha,25-Dihydroxyvitamin D(3) [1,25-(OH) (2)D(3)] can exert its biological actions through binding with the nuclear vitamin D receptor (VDR), a ligand-activated transcription factor. Next to control of bone and mineral homeostasis, these actions include an immunomodulatory effect and a potent growth-inhibitory, antiproliferative or prodifferentiating action on a wide variety of cell types. The molecular mechanisms underlying this antiproliferative action form an intriguing research topic and they remain, although thoroughly studied, not completely understood. Important cell cycle regulators are involved such as cyclins, cyclin dependent kinases and their corresponding inhibitors as well as E2F transcription factors and accompanying pocket proteins. Whether 1,25-(OH)(2)D(3) influences the expression of all these proteins directly through the nuclear VDR or rather in an indirect manner is not always clear. The antiproliferative action makes 1,25-(OH) (2)D(3) a possible therapeutic tool to treat hyperproliferative disorders, among which different types of cancer. Clinical application, however, is severely hampered by calcemic effects such as hypercalcemia, hypercalciuria and increased bone resorption. Rational design of chemically modified 1,25-(OH) (2)D(3)-analogs tries to overcome this problem. As such, several thousands of analogs have been synthesized and evaluated, some of which display the desired dissociation between beneficial antiproliferative and unwanted calcemic effects. A number of those analogs are 'superagonistic' and have a several-fold stronger antiproliferative action than the parent compound. This review focuses on recent findings about the complex mechanisms behind the antiproliferative and prodifferentiating effect of 1,25-(OH) (2)D(3). Furthermore, the mode of action and possible clinical application of chemically modified 1,25-(OH) (2)D(3)-analogs will be discussed.
Assuntos
Inibidores do Crescimento , Vitamina D/análogos & derivados , Vitamina D/farmacologia , Animais , Calcitriol/farmacologia , Proliferação de Células/efeitos dos fármacos , Humanos , Receptores de Calcitriol/efeitos dos fármacos , Esteroides/síntese química , Esteroides/farmacologia , Relação Estrutura-AtividadeRESUMO
Nonsteroidal analogues of 1alpha,25(OH)2D3, lacking either the full five-membered D ring (C-ring analogues) or the full six-membered C ring (D-ring analogues) are more potent inhibitors of cell proliferation or inducers of cell differentiation than is 1alpha,25(OH)2D3. Maximal superagonistic activity was seen for the C-ring analogue with a 24(R)-hydroxyl group in the side chain [30- to 60-fold the activity of 1alpha,25(OH)2D3]. The 19-nor-16-ene-26,27-bishomo C-ring analogue showed the best ratio of antiproliferative to calcemic effects (1275-fold better than 1alpha,25(OH)2D3 and severalfold better than all vitamin D analogues so far described). The analogues are able to stimulate specific vitamin D-dependent genes and are active in transfection assays using an osteocalcin promoter VDRE. Low binding affinity to the vitamin D binding protein, differences in metabolism, or affinity for the vitamin D receptor (VDR) are not the most important explanations for the enhanced intrinsic activity. However, the analogues are able to induce conformational changes in the VDR, which makes the VDR-ligand complex more resistant against protease digestion than is 1alpha,25(OH)2D3. In contrast to 20-epimer steroidal vitamin D analogues, 20-epimer C-ring analogues were less potent than analogues with a natural C-20 configuration. In conclusion, several nonsteroidal vitamin D analogues are superagonists of 1alpha,25(OH)2D3 despite lower receptor affinity and, for the C-ring analogues, higher flexibility of the side chain; moreover, they have a better selectivity profile than all analogues yet published.
Assuntos
Calcitriol/análogos & derivados , Calcitriol/farmacologia , Transdução de Sinais/efeitos dos fármacos , Relação Estrutura-Atividade , Calcitriol/metabolismo , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Células HL-60 , Humanos , Receptores de Calcitriol/agonistas , Receptores de Calcitriol/metabolismoRESUMO
The synthesis of four CD-ring-modified 19-nor-1alpha, 25-dihydroxyvitamin D(3) derivatives lacking C15, referred to as 6C analogues, and diastereomeric at C17 and C20 is described. The synthesis involves an Ireland-Claisen rearrangement of a 3-methyl-substituted ester of (1R)-3-methyl-2-cyclohexen-1-ol as the key step, followed by elaboration of the side chain, transformation into a C8 cyclohexanone derivative, and final Wittig-Horner coupling with the 19-nor A-ring phosphine oxide. Despite possessing a more flexible side chain than the parent hormone, biological evaluation showed an unexpected superagonistic antiproliferative and prodifferentiating activity (10-50 times higher as compared to that of 1alpha,25(OH)(2)D(3)) for the diastereomer with the "natural" configuration at C17 and C20. The other diastereomers exhibit a 25-90% decrease in activity. All four analogues show a decreased binding affinity (45% or less), and their calcemic activity is 4-400 times less than that of 1alpha,25(OH)(2)D(3). The conformational behavior of their side chain was studied using molecular mechanics calculations, and the result is presented as volume maps. A relative activity volume was determined by subtraction of the volume map of the least active analogue from the volume map of the most active one. This shows three regions corresponding to preferred orientations in space of the side chain of the active analogue. One of these regions was found to overlap with the region that is preferentially occupied by the most active of the four diastereomeric 22-methyl-substituted 1alpha,25(OH)(2)D(3) analogues.
Assuntos
Vitamina D/análogos & derivados , Animais , Ligação Competitiva , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Humanos , Queratinócitos , Camundongos , Modelos Moleculares , Conformação Molecular , Estrutura Molecular , Receptores de Calcitriol/metabolismo , Estereoisomerismo , Suínos , Células Tumorais Cultivadas , Vitamina D/químicaRESUMO
The permeability of the blood-brain barrier for atenolol, a hydrophilic beta-adrenergic blocking agent, has been assessed in dogs, by studying the distribution of [11C]atenolol in brain tissue with positron emission tomography. The passage of atenolol into the brain was very limited, but a measurable small net influx into the brain tissues did occur. Osmotic opening of the blood-brain barrier resulted in a marked increase of the atenolol concentrations in brain tissue. The approach described, with sequential non-invasive measurements in brain tissue, is applicable to pharmacokinetic studies of atenolol in man.
Assuntos
Atenolol/farmacologia , Barreira Hematoencefálica/efeitos dos fármacos , Animais , Permeabilidade da Membrana Celular/efeitos dos fármacos , Cães , Injeções Intravenosas , Manitol/farmacologia , Tomografia Computadorizada de EmissãoRESUMO
A canine model was used to evaluate the possibilities offered by positron emission tomography (PET) for the study of drug distribution in the brain during altered states of the blood-brain barrier (BBB). PET was used to monitor the changes in the distribution of [11C]quinidine and [11C]morphine resulting from BBB-disruption by intracarotid infusion of a hyperosmolar mannitol solution. Injection of Evans blue dye allowing post-mortem evaluation of the degree of BBB-opening was used as a reference method. Brain radioactivity concentrations observed after i.v. injection of either [11C] quinidine or [11C]morphine were markedly increased by intracarotid mannitol infusion, whereas they were not affected by saline infusion. For both drugs a close correlation was found between the radioactivity concentrations and the degree of Evans blue staining within the brain hemispheres and within smaller regions of interest corresponding to quadrants of a hemisphere. This parallelism between the findings for radioactivity concentrations and Evans blue staining suggests that PET allows the detection of in-vivo changes in brain distribution of drugs resulting from alterations of the BBB permeability.
Assuntos
Barreira Hematoencefálica , Morfina/metabolismo , Quinidina/metabolismo , Tomografia Computadorizada de Emissão , Animais , Barreira Hematoencefálica/efeitos dos fármacos , Encéfalo/diagnóstico por imagem , Encéfalo/metabolismo , Cães , Azul Evans , Manitol/farmacologia , OsmoseRESUMO
Dot maps used to represent the calculated conformations of the side chain of vitamin D derivatives are improved by replacing dots by coloured balls to create volume maps and to identify particular energy windows. Two procedures to define a relative activity volume, based on a pair of analogs with distinctly different biological activity and conformational behaviour, are presented.
Assuntos
Calcitriol/análogos & derivados , Calcitriol/química , Conformação Molecular , Vitamina D/análogos & derivados , Vitamina D/química , Calorimetria , Simulação por Computador , Modelos Moleculares , Estrutura Molecular , Relação Estrutura-Atividade , TermodinâmicaRESUMO
The 1H and 13C NMR data of DAPRO, alpha- and beta-ODAP were measured at varying pH values and the physical relevance of these data was studied. As a potential way to detoxify the neurotoxin beta-ODAP, its isomerization was studied at room temperature and at 60 degrees C. An unknown hydrolysate is identified as DAPRO.
Assuntos
Diamino Aminoácidos/química , Neurotoxinas/química , beta-Alanina/análogos & derivados , Fabaceae , Concentração de Íons de Hidrogênio , Espectroscopia de Ressonância Magnética , Plantas Medicinais , Estereoisomerismo , beta-Alanina/químicaRESUMO
The discovery that 1alpha,25-dihydroxyvitamin D3 is effective in the inhibition of cellular proliferation and in the induction of cellular differentiation has led to a search for analogues in which these activities and the classical calcemic activity of this hormone are separated. In this context, the synthesis and biological evaluation are reported of the three stereoisomeric CD-ring modified structural analogues in order to enforce a particular and different orientation of the 25-hydroxylated side chain. Comparison of the results of the biological evaluation and conformational analysis of the side chain suggests one defined and "active" geometry.
Assuntos
Calcitriol/análogos & derivados , Calcitriol/química , Calcitriol/farmacologia , Divisão Celular/efeitos dos fármacos , Humanos , Modelos Moleculares , Estrutura Molecular , Análise Espectral , Células Tumorais CultivadasRESUMO
An automated system for the production of 11C-labeled radiopharmaceuticals, using 11C-CH3I as a precursor, has been developed. The whole procedure, including irradiation, production of 11C-CH3I, synthesis of the labeled molecule and isolation of the final product is controlled by a microprocessor. Between 30 and 80 mCi of 5 different radiopharmaceuticals are produced routinely with this system.
Assuntos
Dióxido de Carbono , Isótopos de Carbono , Hidrocarbonetos Iodados , Marcação por Isótopo/instrumentação , Marcação por Isótopo/métodosRESUMO
We used positron emission tomography to monitor the distribution of radioactivity in dog brain and muscle following i.v. administration of 11C-labelled antipyrine, imipramine, and quinidine. Twenty-five sequential scans of a transaxial slice of the head were performed within 90 min; radioactivity in plasma was measured in a gamma-counter. Following i.v. injection of [11C]antipyrine (50 mg kg-1; 9-68 mCi; n = 10), the decay of plasma activity was accompanied by rapid uptake in brain and variable uptake in muscle, immediately followed by a redistribution leading to equalization of the radioactivity in the tissues. Administration of [11C]imipramine (4 mg kg-1; 30-110 mCi; n = 8) was followed by a rapid build-up of a sustained gradient between high brain, and low plasma and muscle radioactivity. After i.v. injection of [11C]quinidine (1 mg kg-1; 11-87 mCi; n = 10), radioactivity in brain was low, with higher activity in plasma and muscle throughout the experiment. Positron emission tomography thus revealed for each drug a distinct pattern of distribution consistent with established properties of the compounds. This technique seems promising for the study of early drug distribution, notwithstanding certain limitations.
Assuntos
Antipirina/farmacocinética , Encéfalo/diagnóstico por imagem , Imipramina/farmacocinética , Quinidina/farmacocinética , Tomografia Computadorizada de Emissão , Animais , Antipirina/sangue , Encéfalo/metabolismo , Radioisótopos de Carbono , Cães , Imipramina/sangue , Músculos/diagnóstico por imagem , Músculos/metabolismo , Quinidina/sangueRESUMO
Positron emission tomography is a potential method for exploring the biochemical behaviour of tumours. In 28 patients with known neoplastic lesions a comparison was made between two agents which are known to be accumulated in malignant tumours, viz. 13N-ammonia and 11C-aminocyclopentane carboxylic acid (ACPC). Absolute concentration of both agents in various tumoural tissues and normal organs was calculated. As a rule a parallelism was found between the two tracers as to their accumulation in a given tumour, although the concentration was often higher for ACPC. In normal tissues the ACPC accumulation was either lower or at most equal to NH3 levels. As tumour tracer ACPC is superior to NH3 because of its higher absolute accumulation in many neoplastic lesions and its lower uptake in various non-tumorous tissues. ACPC concentration in tumours seems to be largely independent of blood flow.